Two-Year Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Medtronic; Boston Scientific Corporation; Siemens Healthineers; Shockwave Medical; Peija Medical; Shenqi Medical Technology; Edwards Lifesciences; Philips
• Advisory board member - JenaValve
• Anatomic eligibility committee member of TRILUMINATE trials and Publications Committee - Abbott
• Screening Committee member of the APOLLO trial, steering committee member of the IMPACT-MR trial, TAVR Publications Committee member - Medtronic